Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial
Authors' conclusion
Bones of RA patients improve with BARI therapy, as shown by an increase in trabecular bone mass and an improvement of biomechanical properties.
Study context
- Population
- Rheumatoid arthritis (RA) patients with pathological bone status and clinical indication of Janus kinase inhibition (JAKi)
- Participants
- 30 patients
- Outcome
- Effect of baricitinib on volumetric BMD, bone microstructure, biomechanics and erosion repair, and on synovial inflammation (HR-CT and MRI)
- Follow-up
- Baseline, week 24 and week 52
Methodological detailssingle-arm, open-label, single-centre, phase 4
- Single-arm
- Open-label
- Single-centre
- Phase 4
Main finding
As reported in the abstract
Trabecular volumetric bone mineral density (vBMD) mean change, mgHA/mm³
6.11
95% CI 0.01–12.26
Estimated stiffness mean change, kN/mm
2.28
95% CI 0.30–4.25
Estimated failure load mean change, N
98.8
95% CI 15.9–181.7
Observational data: associations, not effects.
Further findings
Disease activity (DAS28-ESR), baseline to follow-up
- DAS28-ESR (mean ± SD) improved
- 4.82 ± 0.90 to 2.71 ± 0.83
Synovial inflammation (RAMRIS synovitis score)
- RAMRIS synovitis score improved
- 5.3 [4.2] to 2.7 [3.5]
Safety
- No new safety signals with baricitinib (BARI) treatment
Original publication
Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial. Arthritis Rheumatol. Published 21 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →